Ritter Pharmaceuticals’ Reverse Merger With Qualigen

Reed Smith advised Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) in a reverse merger with Qualigen, Inc., a privately held company, in an all-stock transaction.

Ritter Pharmaceuticals is a developer of therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases.

Qualigen focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases.

The cross-practice Reed Smith team on this transaction was led by corporate partner Jennifer W. Cheng (Picture) with key support from partners Wendy Grasso and Michael Sanders, counsel Sue Nieto, and associates Sheran Sharafi, Nataly Laufer Sultan, Iantha Stewart, Brent McDonough and Emerson Bianchi.

Involved fees earner: Emerson Bianchi – Reed Smith; Jennifer Cheng – Reed Smith; Wendy Grasso – Reed Smith; Nataly Laufer Sultan – Reed Smith; Susan Nieto – Reed Smith; Michael Sanders – Reed Smith; Sheran Sharafi – Reed Smith; Iantha Stewart – Reed Smith;

Law Firms: Reed Smith;

Clients: Ritter Pharmaceuticals;

Print Friendly, PDF & Email

Author: Ambrogio Visconti